Applied DNA Sciences, Inc.

306 articles with Applied DNA Sciences, Inc.

• Applied DNA Sciences and A&E Introduce Anti-Counterfeiting Technology for Sustainable Sewing Threads

  6/8/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and American & Efird, (A&E), the world’s foremost thread manufacturer, today announced A&E’s INTEGRITY™ advanced identification thread technology is available for its ECO100 recycled sewing thread line

• Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

  6/7/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated with the Applied DNA-Evvivax LinearDNA™ COVID-19 vaccine

• Applied DNA Adds First Summer Camp for safeCircle Pooled COVID-19 Surveillance Testing

  6/2/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing contract with Camp Chateaugay , an overnight summer camp program for teens and kids based in New York’s Adirondack Mountain region

• Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation-Detection Panel, Highlights Ability to Rapidly Identify Mutations and Probable Variants

  5/26/2021

  - Linea™ COVID-19 SGS™ Mutation Panel Can Identify ‘Mutations of Therapeutic Concern’ that May Lessen Response to Certain Therapies - - As the Prelude to Whole Viral Genome Sequencing, Mutation Panel Empowers Pursuit of Specific Variant Lineages and Can Minimize Sequencing of Wild Type Virus - - Company Initiates Development of New Assay to Characterize B.1.617 (Indian) Variant and Sub-Variants -  

• Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and Press Release Published 12 May 2021

  5/14/2021

  Applied DNA Sciences, Inc., clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit and certain information contained in its previously disseminated 12 May 2021 press release relating to the U.S. Food and Drug Administration’s grant of a re-issued Emergency Use Authorization that expands the Assay Kit for asymptomatic serial screening testing.

• Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues

  5/13/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the three and six months ended March 31, 2021.

• Applied DNA Receives CLIA Certification, Enabling High Throughput Diagnostic COVID-19 Testing

  5/11/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing, announced that its Applied DNA Clinical Labs, LLC subsidiary received CLIA certification from the New York State Department of Health Clinical Laboratory Evaluation Program for COVID-19 testing using EUA-authorized methods and devices.

• Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021

  5/7/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day.

• Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

  5/6/2021

  - Manufactured by an enzyme and without bacteria, LinearDNA vaccine candidate is virus-free, plasmid-free DNA - - Vaccine candidate induced neutralizing titers in 100% of trial cohort - - Based on positive study results, companies plan to accelerate clinical trial with commercial minks -

• Applied DNA Secures Amendment to Master Services Agreement and Fourth Blanket Purchase Order from Linea™ COVID-19 Assay Kit Customer

  4/26/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it secured an amendment to a Master Services Agreement (MSA) with an existing customer of its Linea™ COVID-19 Assay Kit (the “Assay Kit”).

• Applied DNA Provides Preliminary Estimated Fiscal Second Quarter 2021 Revenue Range and Business Update

  4/21/2021

  - Anticipates Revenues in the Range of $2.5 Million to $2.7 Million Driven by COVID-19 Testing and Diagnostics Sales - - Announces Full Loan Forgiveness under Paycheck Protection Program – - NYS Department of Health Completes Re-Inspection of ADCL -

• Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

  4/8/2021

  Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

• Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

  4/7/2021

  - Offers Valuable Real-Time Surveillance of SARS-CoV-2 Mutations and VoCs-  - Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform - - Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine -

• Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

  4/1/2021

  - Shorrock Rejoins Company; Appointment Underscores Company’s Pursuit of Commercial Activities In Highly Regulated End-Markets, Including Biotherapeutics and Diagnostics -

• Applied DNA Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests

  3/11/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the receipt of a purchase order for its Linea™ COVID-19 Assay Kit (the “Assay Kit”) and consumables to conduct 10,000 tests under a Master Services Agreement with an existing customer.

• Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to Boost SARS-CoV-2 Variant Detection and Tracking Nationally

  3/9/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the launch of its Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel (the “SGS Panel”) to enhance the utility of limited Next Generation Sequencing

• Applied DNA to Participate in Upcoming Conferences

  3/8/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences.

• Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

  3/2/2021

  - Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models - - Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines -

• Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM College

  2/19/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and LIM College, a midtown Manhattan-based leader in education for the business of fashion, today announced that Applied DNA will provide COVID-19 surveillance testing for all in-person students

• Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range

  2/11/2021

  – Reports Revenues of $1.6 Million Compared with $634,000 in the Year-Ago Period and $314,000 in the Fourth Quarter of Fiscal 2020 – - Leverages EUA-Authorized Assay’s Ability to Discriminate for Certain SARS-CoV-2 Variants to Pursue Market for Genomic Surveillance, Receives Initial Orders –